Vaccines

Latest News


CME Content


Researchers have spent a century trying to develop a vaccine against malaria, one of the world’s biggest killers. The first shot to be approved, two years ago, is 30% effective. A new one, in the works for three decades, has a reported 77% efficacy and a licensee with the capacity to produce 200 million doses a year.

Despite decades of research, no available vaccine targets respiratory syncytial virus (RSV), a disease that causes hundreds of thousands of deaths worldwide among young children and older adults. Interim results of two late-stage trials of Pfizer’sRSV prefusion F vaccine suggest the vaccine is efficacious, although the low RSV infection rates during the high COVID-19 pandemic years limited some of the findings.

Results reported today on the JAMA website show no benefit from repurposing the SSRI as a COVID-19 treatment drug. Earlier results suggesting that fluvoxamine might be an effective treatment were from trials conducted earlier in the pandemic when vaccines weren’t available and other variants were circulating.